Introduction {#s0005}
============

Psoriasis (PSO) is a chronic inflammatory disease with manifestations that include red, scaly, itchy and/or painful patches, plaques, or papules. These symptoms typically have a predilection for the scalp and extensor surfaces but can be widespread in severe cases. Up to 40% of patients with PSO will develop psoriatic arthritis (PsA), typically within 5 to 10 years of PSO disease onset ([@bb0340]). PsA is a chronic rheumatic disease characterized by synovitis, enthesitis, dactylitis, and spondylitis ([@bb0340]). Joint involvement can precede skin manifestations or may occur in parallel in a minority number of cases ([@bb0260], [@bb0305]). Beyond PsA, people with PSO are also at increased risk of developing a range of comorbidities related to the metabolic syndrome, including hypertension, hyperlipidemia, obesity, and type 2 diabetes mellitus ([@bb0025], [@bb0435]).

The prevalence of PSO varies worldwide ([@bb0495]); in countries with a predominantly Caucasian population, it is frequently reported to be between 1% and 3% ([@bb0265], [@bb0340]). Disease onset is bimodal, with one incidence peak occurring at 15 to 30 years of age and the second between 50 to 60 years ([@bb0035], [@bb0140], [@bb0250]). However, \> 75% of cases present before the age of 40 years ([@bb0465]).

For women, a diagnosis of PSO (average age: 28 years; [@bb0310], [@bb0465]) and therapy initiation often overlap with peak reproductive years (18-45 years; [@bb0140], [@bb0250]), which can pose specific challenges for treatment. Formal treatment guidelines for women of childbearing age with PSO are not currently available, but U.S. and European drug labeling now summarizes safety data associated with pregnancy and lactation to help inform treatment selection for this patient population.

Women with PSO can experience disease activity fluctuations with hormonal changes and with each stage of the journey to motherhood ([@bb0090]). In a prospective study of 163,763 women (n = 1253 incident cases of PSO), irregular menstrual cycles and surgical menopause were associated with a higher risk of PSO, whereas there was a trend among younger women toward a lower PSO risk in those who had experienced multiple births and longer breastfeeding periods ([@bb0500]).

Burden of psoriasis for women {#s0010}
=============================

PSO can have a profoundly negative impact on patients' quality of life. In a survey of patients with PSO or PsA (n = 5604) conducted by the National Psoriasis Foundation (NPF), the majority of patients felt that PSO was a problem in their daily life (94%), affected their overall emotional well-being (88%), and interfered with their enjoyment of life (82%; [@bb0015]). The emotional impact of PSO was greater in patients with severe (\> 10% self-reported body surface area \[BSA\] involvement) compared with those with mild disease (\< 3% BSA; [@bb0015]).

Women with PSO and PsA show reductions in quality of life in all domains assessed by the 36-Item Short Form Health Survey questionnaire ([@bb0425], [@bb0485]). According to the World Psoriasis Happiness Report 2017, women with severe PSO experience a greater negative impact on their happiness compared with men, with gaps of − 18.5% vs. − 11.3%, respectively, compared with women and men in the general population ([@bb0295]). Furthermore, women with PSO are more likely to experience stress (\> 60% vs. 42%) and loneliness (25-28% vs. 19-24%) than men with the disease ([@bb0295]). Among patients with PsA, women also appear to have higher disability and fatigue severity scores ([@bb0195]).

Women report higher (worse) Dermatology Life Quality Index scores than men, despite scoring lower (better) on the Psoriasis Area Severity Index (n = 2450), which suggests a mismatch between subjective and objective disease activity measures ([@bb0290]). This finding highlights the importance of considering subjective measures in the treatment decision-making process to ensure that female patients are not undertreated ([@bb0290]).

Patients with PSO and PsA have an increased risk of depression, anxiety, and suicidality ([@bb0270], [@bb0335]). In a study using prospectively collected data from the Organization of Teratology Information Specialists (OTIS) Autoimmune Diseases in Pregnancy Project, the prevalence of depression in women with PSO was approximately two-fold higher compared with women without the condition (21% vs. 12%, respectively; *p* = .03; [@bb0035]).

PSO can also lead to sexual impairment. In response to a questionnaire (n = 481), a quarter of Dutch Psoriasis Association patients reported a decline in sexual activity after disease onset, with women affected to a greater extent than men (33% vs. 19%, respectively; *p* \< .0001; [@bb0345]). Approximately half of the women with PSO who responded had sexual dysfunction (n = 88 of 181 patients; Female Sexual Function Index cutoff score: ≤ 26.55). Moreover, using the Female Sexual Distress Scale (cutoff score: ≥ 15), 38% of women with PSO showed sexual distress. Women with current genital lesions exhibited significantly more sexual distress versus women not currently affected (*p* = .001; [@bb0345]). In a study of adult patients with PSO (n = 354) in the U.S. and Ireland, 63% reported experiencing genital PSO at some stage ([@bb0420]). Of the patients with currently active genital PSO, 43% reported a decreased frequency of intercourse. Of note, pain, burning, and discomfort during intercourse were reported significantly more frequently by women than men ([@bb0420]). PsA is also known to interfere with the physical ability to have intercourse, especially when the lower back and sacroiliac joints are involved ([@bb0210], [@bb0275]).

Compared with men, women experience higher stigmatization as a result of PSO, as assessed by the Feelings of Stigmatization Questionnaire (mean total score of 93.2 vs. 78.0; *p* = .001), which includes questions on anticipation of rejection, feelings of being flawed, sensitivity to the opinions of others, and secretiveness ([@bb0220]).

Health care professionals (HCPs) can support and reassure patients by initiating discussions around intimacy and dating in an open and honest manner. Guidance on the management of PSO in an intimate relationship and on using make-up and clothing to improve confidence is available via PSO patient support groups and online ([@bb0390], [@bb0385]). Women with PSO may also require support with ascertaining what expectations to have of their therapy; patients may not always be aware of the optimal achievable condition of their skin, particularly if they do not consult a dermatologist who prescribes the full repertoire of PSO and PsA treatments, including systemic or biologic agents.

Management of psoriasis in women of childbearing age {#s0015}
====================================================

PSO has a unique impact on women of childbearing age. The condition is not thought to affect fertility ([@bb0405]); however, a 22% lower likelihood of pregnancy has been reported among women with PSO compared with the overall population ([@bb0085]). The underlying reasons are likely complex and may include voluntary childlessness, concern with regard to disease activity during pregnancy or postpartum, fear of the effect of PSO therapy on pregnancy, reduced intimacy due to embarassment, and/or physical inability to have intercourse.

Timely initiation of discussions about family planning and ongoing dialogue with HCPs are critical for all women of childbearing age. The implications of treatment must be considered in all women with PSO who are sexually active, even if they are not actively planning to start a family. This is especially pertinent in light of research suggesting that approximately half of all pregnancies are unplanned, including among the PSO and PsA patient population ([@bb0240], [@bb0375]). Furthermore, most women discover they are pregnant between weeks 4 and 7 (calculated from the date of the last menstrual period), which corresponds to a fetal gestational age of 2 to 5 weeks and coincides with a critical window of early fetal development ([@bb0005]). Therefore, women of childbearing age may benefit from counselling to avoid unintentional teratogen exposure ([@bb0405]). There are many safe treatment options for this patient group, as discussed in detail herein, but certain therapies mandate the use of birth control measures.

Women with PSO should be made aware also of the importance of notifying their treating physician of a potential pregnancy. A recent U.S. NPF survey (n = 141) revealed that of women with PSO who had experienced pregnancy (n = 66), only 41% had informed their HCP of the pregnancy immediately; while 21% did not notify their HCP at any point ([@bb0280]).

Psoriasis and pregnancy {#s0020}
=======================

PSO activity often improves or stabilizes during pregnancy, and a subset of women show a marked improvement in their skin condition ([@bb0370]). In a study investigating the effect of hormonal fluctuations around pregnancy on PSO (n = 47), 55% of women reported improvement and 21% indicated no change ([@bb0370]). In patients with ≥ 10% psoriatic BSA who experienced improvement (n = 16; mean BSA: 40%), lesions decreased by \> 80% between the first and third trimesters ([@bb0370]). However, there is evidence that women with PSO and PsA may also experience skin disease worsening (or stable high disease activity) during pregnancy (PSO: \~ 23%; PsA: \~ 9%; [@bb0370], [@bb0395], [@bb0480]).

Pregnancy outcomes data for women with PSO have shown variable results ([Table 1](#t0005){ref-type="table"}), and further studies are warranted. In a 2016 systematic review including nine observational studies (six studies rated as good quality), there was no clear evidence of a consistently increased risk of adverse pregnancy outcomes for women with PSO ([@bb0055]). Furthermore, a study using data from a U.S. nationwide inpatient sample database (2003-2011; n = 11,204 women with PSO or PsA) revealed that, after adjusting for potential confounders, maternal PSO/PsA had no significant impact on inpatient mortality or fetal death. The prevalence of preterm delivery, premature rupture of membranes, postpartum hemorrhage, and cesarean delivery was similar between the PSO/PsA population and the control group ([@bb0060]).Table 1Study data evaluating pregnancy outcomes in women with PSO and PsA ([@bb0045], [@bb0135], [@bb0215], [@bb0315], [@bb0430], [@bb0505], [@bb0075])Table 1[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11]

However, certain studies have found a link between disease activity and pregnancy complications or adverse pregnancy outcomes. In a recent cohort study using prospectively collected data from Denmark and Sweden (April 2007-December 2012; n = 8097 births to PSO/PsA mothers), an increased risk of gestational diabetes, gestational hypertension, preeclampsia, and emergency cesarean delivery was reported in women with PSO ([@bb0075]). The lifestyle factors and comorbidities adjusted for by the authors included country, maternal age and parity, smoking status, body mass index, depression, diabetes, and hypertension ([@bb0075]). The risks were higher for women with severe PSO, who were also found to have an increased risk of moderate preterm birth (32-36 weeks) and low birth weight ([@bb0075]). The increased risk of low birth weight and preeclampsia in women with severe PSO is in accordance with findings from a previous cohort study that evaluated pregnancy outcomes in 1483 pregnant women with PSO ([Table 1](#t0005){ref-type="table"}; [@bb0505]). This analysis was adjusted for characteristics of the infant (sex and parity), the mother (age, education level, marital status, income, gestational hypertension, diabetes, anemia, and coronary heart disease), and the father (age and education level).

Data on pregnancy outcomes in women with PsA are more limited ([@bb0365]). The cohort study by Broms et al. identified an increased risk of gestational hypertension and preeclampsia for women with PsA (after adjusting for confounding factors as mentioned; [@bb0075]). Recently presented data from a Swedish cohort study (2007-2014) also found an adjusted odds ratio (aOR) of preterm birth of 1.80 (95% confidence interval \[CI\], 1.22-2.64) among 397 PsA pregnancies (n = 289 mothers; [@bb0410]). However, the aOR of preeclampsia, gestational diabetes and stillbirth did not differ between the comparator groups ([@bb0410]). The authors of the study adjusted for the mother's country of birth, education level, smoking status, body mass index, parity, age, and year of birth, but not for comorbidities such as diabetes mellitus. Data from a large prospective cohort analysis of women enrolled as part of the OTIS Autoimmune Disease in Pregnancy Project before 20 weeks gestation (2004-2018) also showed that PsA was associated with an increased risk for moderate preterm delivery (adjusted risk ratio \[aRR\]: 1.81; 95% CI, 1.01-3.26), preterm labor (aRR: 2.05; 95% CI, 1.21-3.48), oligohydramnios (aRR: 3.79; 95% CI, 1.34-10.74), and cesarian section (aRR: 1.63; 95% CI, 1.26-2.12) versus the healthy comparator group ([@bb0445]). However, adjustment for confounding factors was not reported in this abstract.

Postpartum period {#s0025}
-----------------

Disease activity may improve during pregnancy, but many women with PSO experience flares postpartum ([@bb0370], [@bb0395]). In U.S. patients with PSO, of 1239 live pregnancies identified in the MarketScan database (January 2010-September 2016), 1897 flares were recorded. The average monthly flare rates revealed an increased risk postpartum: 71.3, 77.4, and 126.1 flares per month were calculated for the pre-conception, pregnancy, and postpartum periods, respectively ([@bb9100]). [@bb0370] demonstrated that psoriatic BSA approximately doubled between 30 weeks' gestation and 6 weeks postpartum. However, the increased BSA values observed did not exceed those of the first trimester, suggesting a return to the patients' baseline status ([@bb0370]).

Estrogen fluctuations are speculated to be associated with BSA improvement during pregnancy (elevated levels) and disease worsening postpartum (subsequent reduction; [@bb0065], [@bb0370]), but no definitive evidence exists in support of a causative effect ([@bb0145]). In addition, psoriatic treatments during pregnancy are commonly discontinued ([@bb0280], [@bb0285], [@bb0480]), and the impact of therapy cessation on postpartum disease activity cannot be discounted.

A recent retrospective study found no significant change in PsA disease activity during pregnancy, but a statistically significant aggravation was observed during the postpartum period compared with the third trimester (n = 33 live births; *p* = .01; [@bb0050]). Similarly, in a prospective multicenter study including 103 women with PsA (n = 108 pregnancies) from a Norwegian nationwide register, PsA disease activity decreased during pregnancy and increased within 6 months postpartum ([@bb0480]). However, disease activity from planning to 12 months after delivery was stable, with 75% of women with PsA shown to be in remission (Disease Activity Score-28 \[DAS28\] ≤ 2.6) or to have low disease activity (2.6 \< DAS28 ≤ 3.2) at these time points ([@bb0480]). Overall disease stability was observed despite disease-modifying antirheumatic drug use (synthetic, biologic, or both) decreasing from 58% prior to pregnancy to 17% in late pregnancy ([@bb0480]).

On the other hand, discontinuation of biologic treatment before pregnancy or during the first trimester (n = 15 of 21 pregnancies) was associated with significant disease worsening during pregnancy and in the postpartum period (odds ratio: 7; 95% CI, 0.5-98.6), but no significant changes were reported in the small number of patients who continued on biologic therapy beyond the first trimester (n = 6; anti-tumor necrosis factor \[anti-TNF\]: n = 5; ustekinumab: n = 1; [@bb0050]). In line with these findings, although only a small number of women with PsA used anti-TNFs during pregnancy (n = 7) in the Norwegian study, disease activity 6 months postpartum was significantly lower in this group (mean DAS28-C-reactive protein with anti-TNF: 2.22 vs. without anti-TNF: 2.72; *p* = .043; [@bb0480]).

If a mother can and chooses to breastfeed, it can benefit both the mother and the child ([@bb0230]). However, nursing mothers are prone to nipple pain due to dermatitis and the development of new psoriasis plaques (koebnerization; [Fig. 1](#f0005){ref-type="fig"}; [@bb0225]). PSO and PsA management before, during, and after pregnancy is highly important to achieve optimal outcomes for both mothers and infants ([@bb9200]).Fig. 1Koebnerization: Development of new psoriasis plaques on the nipple due to infant suckling (image courtesy of Jenny Murase, MD, Department of Dermatology, University of California San Francisco and Palo Alto Medical Foundation Medical Group).Fig. 1

Unmet needs of women with psoriasis and psoriatic arthritis on their journey to motherhood {#s0030}
==========================================================================================

Pre-conception {#s0035}
--------------

Women with PSO planning a pregnancy require support from their HCPs with initiating discussions about family planning. The Patient Journey survey of women of childbearing age (18-45 years) with psoriatic diseases (PSO: n = 367; PsA: n = 142) from the U.S., Japan, and the European Union 5 (EU5; Germany, France, Italy, Spain, and the United Kingdom) revealed that before pregnancy, more than three-quarters of women with PSO and PsA had to initiate these discussions with HCPs themselves ([@bb0375]). This finding was corroborated by the NPF survey, which found that only 7% of patients who discussed family planning with their treating physician stated that this discussion was initiated by their HCP ([@bb0280]).

Inadequate information and guidance from HCPs may contribute to women delaying pregnancy or seeking information elsewhere. More than half of women with PsA and a quarter of women with PSO admitted delaying their decision to become a mother; their main fear was passing on health issues to their child ([@bb0375]). According to the NPF survey, most patients with PSO planning to become pregnant sought advice from the internet (88%); only 21% had consulted their treating physician ([@bb0280]).

HCPs should also be able to confidently address patients' questions on the heritability of PSO and PsA. If only one parent has PSO, a child will have a 28% lifetime risk of developing the condition; if both parents have PSO, the risk increases to 65% ([@bb0460]).

Pregnancy {#s0040}
---------

Recent surveys have highlighted several unmet needs of women with PSO and PsA around pregnancy. The Patient Journey survey indicated that women lack information on the impact of treatment decisions on pregnancy (PSO: 31%; PsA: 40%; [@bb0375]). Furthermore, only 28% of women with PSO had a treatment plan aligned between different HCPs (only 18% for women with PSO on biologics) compared with 64% for women with PsA ([@bb0375]).

The U.S. NPF survey (n = 141) revealed that during pregnancy, 65% of patients who had been pregnant stopped treatment (of any type), 79% of whom did so out of fear of harming their baby ([@bb0280]). In 40% of cases where patients had stopped all treatment for PSO, the decision was initiated by the patient themselves; in 47% of cases, treatment was stopped by their treatment provider ([@bb0280]). Of the patients who stopped treatment, 44% experienced a worsening in the severity of their disease, but most patients did not have a plan for flare management during pregnancy (≥ 65%; [@bb0280]).

Postpartum {#s0045}
----------

A disease management plan for new mothers is particularly important, owing to the increased risk of postpartum flares. However, the NPF survey showed that of patients who had experienced a pregnancy and had stopped all treatment, almost a quarter had not been advised on restarting treatment postpartum ([@bb0370]). Misconceptions during this phase are also common. The Patient Journey survey revealed that 44% of women with PSO and 78% of women with PsA felt they had to choose between treatment or breastfeeding ([@bb0375]. Furthermore, up to a quarter of women felt they lacked information on the impact of treatment decisions on breastfeeding (PSO: 16%; PsA: 24%; [@bb0375]). According to the survey, fewer than half of patients with PSO (46%) consulted a dermatologist during pregnancy (first and/or second and/or third trimester), compared with 86% who visited an obstetrician/gynecologist ([@bb0375].

Alignment with a multidisciplinary team for patient-centric care can improve the patient experience and prevent conflicting recommendations ([@bb0205]). Patients and family members should be encouraged to play an active role in the development of their plan of care and coordination of their care team. This strategy helps patients to better understand their options, empowers them to make their values and preferences known, and ensures that they have understood the consequences of any decisions made ([@bb0040]).

Treatment of psoriasis/psoriatic arthritis and options compatible with pregnancy {#s0050}
================================================================================

Many treatment options are available for PSO and PsA, including topical agents, phototherapy, oral systemic agents and biologics. Of note, women of childbearing age (18-44 years) with PSO were reported to undergo more treatment changes than any other cohort assessed (i.e., men aged 18-44 years, men aged 45-65 years, and women aged 45-65 years), which can be an indicator of poor disease control ([@bb0010], [@bb0450]) or increased focus on appearance. This group of patients was also the most likely to discontinue treatment ([@bb0285]).

Balancing the risk of PSO/PsA treatment with the risk of uncontrolled disease is critically important in women of reproductive age, but it can be challenging for physicians ([@bb9200], [@bb0405]). New U.S. Food and Drug Administration labeling now summarizes data associated with fertility, pregnancy, and lactation to facilitate effective discussions around the risks and benefits of drugs with patients, supporting informed decisions. European Medicines Agency guidelines also allow the recommendation of medication use during pregnancy and breastfeeding. If no increased incidence of malformations is observed within at least 300 or 1000 first trimester--exposed, prospectively collected pregnancies with known pregnancy outcomes, the conclusion might be reached that a drug is not responsible for a 10-fold, 2-fold, or more increase of the overall incidence of malformations ([@bb0160]).

Pregnancy outcomes data are increasingly available, and ongoing studies, such as the MotherToBaby study using the regulatory body-recognized OTIS registry, provide further valuable information ([@bb0360]). HCPs have a responsibility to interpret emerging safety data in a timely manner and work with their patients to create a customized disease management plan for all women of reproductive age, irrespective of family planning intentions. A number of articles provide guidance on the treatment of women of childbearing age with PSO or PsA ([@bb0235], [@bb0380], [@bb0400], [@bb0405], [@bb0440]). However, treatment guidelines for PSO, similar to those developed for the management of rheumatic diseases ([@bb0180], [@bb0185], [@bb0200]), are still urgently needed.

Topical treatments {#s0055}
------------------

Topical therapies used in the management of PSO include anthralin, calcipotriol, coal tar, corticosteroids, salicylic acid, tacrolimus, and tazarotene. Many topical drugs can be used during pregnancy, but others are unsuitable. Topical agents that have suspected or known mutagenic or teratogenic properties include anthralin and tazarotene. Coal tar has been shown to have mutagenic potential in animal models when applied to extensive surface areas ([Table 2](#t0010){ref-type="table"}). Topical corticosteroid use has also been implicated in the formation of striae on the breasts during breastfeeding, when the skin is rapidly expanding and contracting ([@bb0235], [@bb0350]).Table 2Topical treatment options and compatibility during pregnancy and breastfeeding[a](#tf0005){ref-type="table-fn"}Table 2Topical treatmentsEvidence during pregnancyKey advice during pregnancyKey advice during breastfeedingAnthralin ([@bb0455])No data in humans**Avoid** or only use if clearly neededOnly use if potential benefit justifies potential risk to infantCalcipotriol ([@bb0300])No data in humansUse only on small surfaces when no alternatives exist ([@bb0380])Compatible; limit to \< 20% surface area and doses \< 10,000 IU/day ([@bb0380], [@bb0080])Coal tar ([@bb0380], [@bb0405])Minimal data in humans**Avoid**; potentially mutagenic/carcinogenic (animal study data; [@bb0380])**Avoid** or use minimally ([@bb0080])Corticosteroids ([@bb0190])Potent corticosteroids may be associated with increased risk of low birth weight at doses \> 300 g ([@bb0115], [@bb0120])Use of low- to moderate-potency topical corticosteroids in short durations is acceptable ([@bb0030], [@bb0110])Compatible, except for Class I (**avoid**; [@bb0440]); avoid use of high-potency corticosteroids on the nipple ([@bb0080])Salicylic acid ([@bb0175])Limited data in humansRestrict use to limited local application for limited time ([@bb0380])Compatible for local, topical use; avoid use on breastsTacrolimus ([@bb0020])Minimal data in humansUse only on small surfaces when no alternatives exist ([@bb0380])Only use sparingly and not directly on the nipple ([@bb0080])Tazarotene ([@bb9300])Teratogen**AvoidAvoid** ([@bb0380])[^12]

The use of class 1 corticosteroids on the nipples should be avoided. A 2015 Cochrane systematic review of 14 randomized controlled trials and cohort studies on the use of topical corticosteroids in pregnant women found no association between maternal exposure and any of the pregnancy outcomes assessed ([@bb0120]). However, the risk of low birth weight significantly increased when the dose of potent (to very potent) topical corticosteroids exceeded 300 g (aRR: 7.74; 95% CI, 1.49-40.11; *p* = .02; [@bb0115]).

Phototherapy {#s0060}
------------

Phototherapy with broadband and narrowband ultraviolet (UV)-B is considered safe during pregnancy and breastfeeding ([@bb0405]). Owing to the potential for maternal folate photodegradation with this treatment, and the association of folate deficiency with neural tube defects, ensuring that women of childbearing age receive adequate folic acid supplementation is an important consideration ([@bb0150], [@bb0380], [@bb0405]). Furthermore, due to an increased risk of melasma, the use of facial shielding is recommended to prevent exacerbation ([@bb0380]). Conversely, psoralen and UV-A therapy is contraindicated during pregnancy due to the mutagenic and teratogenic properties of psoralen ([@bb0380], [@bb0405]).

Systemic agents {#s0065}
---------------

The use of certain oral systemic PSO treatments is also incompatible with pregnancy, including oral psoralen, methotrexate, and acitretin, which have been linked to teratogenic effects and should be avoided in women of childbearing age ([@bb0380]). Cyclosporin is generally considered compatible with pregnancy, although the drug may be associated with an increased risk of low birth weight and prematurity ([@bb0380]). Cyclosporin can cause maternal hypertension; thus, its reservation as a rescue therapy for severe PSO has been recommended ([@bb0380]). Several societies have developed treatment recommendations around the use of systemic agents during pregnancy and breastfeeding ([@bb0030], [@bb0350], [@bb9200]).

Biologic therapies {#s0070}
------------------

Anti-TNF treatments are commonly used to treat PSO, and data are increasingly emerging on their safety around pregnancy ([@bb0235]). The Fc-free anti-TNF certolizumab pegol (CZP) is the only biologic agent with clinical trial data in its label supporting potential use in both pregnancy and breastfeeding for chronic inflammatory diseases ([@bb0165], [@bb0475]). Published in 2017, two prospective studies showed a lack of placental transfer of CZP from mothers to infants (CRIB) ([@bb0325]), and no to minimal transfer from plasma into breast milk (CRADLE) ([@bb0125]). Furthermore, a recent pharmacovigilance safety database analysis (n = 528 prospective pregnancies with known outcomes with maternal exposure to CZP, including 10 twins) demonstrated no teratogenic effect of CZP when compared with the general population in the U.S. and European Union, nor an increased risk of fetal death, providing further reassurance for women of childbearing age considering treatment with CZP ([@bb0130]). More recently, the adalimumab and etanercept labels were also updated to allow potential use during pregnancy, while acknowledging that they may cross the placenta ([@bb0155], [@bb0170], [@bb0470]). Adalimumab can also be used during breastfeeding, based on limited evidence in the published literature.

Two MothertoBaby/OTIS studies investigating pregnancy outcomes in women with chronic inflammatory diseases after exposure to anti-TNFs (etanercept and adalimumab) have so far been completed. The final publications for these studies are expected imminently ([@bb0100]). An increase in major birth defects with etanercept compared with disease-matched groups was indicated (2005-2012; n = 370 exposed; aOR: 2.77; 95% CI, 1.04-7.35; [@bb0095]). However, a drug-related effect was not supported due to the lack of a specific pattern of defects and the minimal placental transfer of etanercept anticipated in early pregnancy ([@bb0095]).

In another recent observational multi-country registry study (Sweden, Denmark, and Finland), no increased risk of birth defects, preterm birth, or infections was observed in the offspring of mothers with chronic inflammatory diseases who were treated with etanercept (n = 425 pregnancies exposed during the first trimester) compared with mothers who were treated with nonbiologic systemic treatment (n = 3508) during pregnancy. The odds ratio for major birth defects in women exposed to etanercept during the first trimester compared with nonbiologic treatment during pregnancy was 0.96 (95% CI, 0.58-1.60) when adjusted for country, maternal disease, parity, maternal age, and smoking status in early pregnancy ([@bb0245]). The adalimumab MothertoBaby/OTIS study (2004-2014; n = 257 exposed; aOR for major birth defects: 0.91; 95% CI, 0.37-2.23\]) also found no evidence of a specific pattern of major birth defects in the exposed cohort ([@bb0105]). Furthermore, the results of this study were reassuring for every outcome examined, including spontaneous abortion and preterm delivery ([@bb0105]).

A recent update article on biologic safety for patients with PSO during pregnancy recommends that infants born to mothers treated with anti-TNF therapies during pregnancy should not be administered live vaccinations (e.g., Bacillus Calmette-Guérin (BCG) or rotavirus vaccines) for at least 6 months after birth due to an increased risk of infection ([@bb9200]),^3^ advice that is also included in the drug package inserts. The only anti-TNF label that differs with respect to vaccination recommendations is that of CZP, based on data demonstrating that CZP levels are undetectable at weeks 4 and 8 after delivery in the plasma of infants exposed in utero ([@bb0325]). Accordingly, the U.S. and EU CZP labels state that the theoretical risk of live or live-attenuated vaccine administration to infants exposed to CZP in utero should be weighed against the benefits of these vaccinations ([@bb0165], [@bb0475]). Inactive vaccinations can be administered per routine practice ([@bb9200]).

Despite the increasing availability of reassuring data on the use of biologics during pregnancy and breastfeeding, rates of biologic use among women of childbearing age have been reported to be lower compared with those of women of all ages ([@bb0285]).

A recent article on biologic safety states that, although relatively limited data are available on biologic use during pregnancy and lactation, these drugs may be considered appropriate for patients with PSO ([@bb9200]). Moreover, anti-TNF agents should be considered over monoclonal antibodies directed against interleukin (IL) 12/23 or IL-17, owing to the greater availability of safety data for anti-TNF therapies ([@bb9200]). In a systematic meta-analysis of 13 studies in patients with chronic inflammatory diseases, women exposed to anti-TNFs during pregnancy had outcomes comparable to those of women who did not receive anti-TNFs ([@bb0255]).

The more recent anti-IL agents (immunoglobulin \[Ig\] G monoclonal antibodies) are thought to be actively transported across the placenta ([@bb0235]) in a manner similar to IgG anti-TNFs (e.g., adalimumab) but unlike certolizumab pegol, as previously discussed. Pregnancy outcomes data in women with PSO, PsA, or Crohn's disease from the Janssen Biotech safety database (through 2017; prospective: n = 130; retrospective: n = 76) identified no specific risks with exposure to the anti-IL 12/23 ustekinumab during pregnancy or within 2 months prior to conception ([@bb0320]).

Furthermore, a recent analysis of safety outcomes with maternal or paternal exposure to the anti-IL 17A secukinumab from the Novartis global safety database (n = 153 pregnancies with known outcomes) found no safety signals with regard to spontaneous abortions or congenital malformations ([@bb0490]). These results are reassuring, but the majority of patients discontinued treatment during the first trimester, which is prior to the anticipated placental transfer of secukinumab. Overall, safety data on anti-IL agents are currently scarce, and because their mechanism of action is distinct from that of anti-TNFs, large pharmacovigilance studies on the safety of these agents during pregnancy are needed. At present, the ustekinumab and secukinumab labels suggest avoidance of their use during pregnancy as a precautionary measure, due to the lack of adequate data on use in pregnant women. No clinical data on the use of the newer, small molecule apremilast during pregnancy are available at present; however, a pregnancy registry has been established (NCT02775500; [@bb0355]).

Despite the importance of HCPs being adequately informed about treating women of childbearing age with anti-TNFs, a recent physicians' survey conducted in the EU5 and U.S. suggested that dermatologists (EU5: n = 135 \[November-December 2017\]; U.S.: n = 53 \[July 2017\]) were the least likely to prescribe anti-TNFs for women with chronic inflammatory diseases compared with rheumatologists (EU5/U.S.) and gastroenterologists (U.S. only; [@bb0415]). Although more than half of participating dermatologists across both regions agreed that controlled disease reduces the risk of pregnancy complications, their comfort with prescribing anti-TNF therapies consistently declined with the onset of family planning, particularly in Europe ([Fig. 2](#f0010){ref-type="fig"}; [@bb0415]). EU5 dermatologists (83%) were also more likely to recommend discontinuation of anti-TNFs before conception than U.S. dermatologists (57%) and to agree that women should stop anti-TNF therapy once pregnant (EU5: 72%; U.S.: 45%; [@bb0415]). Possible explanations for this difference may be the fact that fewer EU5 dermatologists agreed on making disease control during pregnancy their priority, coupled with more EU5 than U.S. dermatologists being very concerned about adverse events in pregnant women taking anti-TNFs.Fig. 2Dermatologists' level of comfort with women of childbearing age being prescribed anti-tumor necrosis factor therapy (adapted from [@bb0415]) HCP = health care professional; pts = patients; TNF = tumor necrosis factor; WoCBA = women of childbearing age.Fig. 2

Biologics are considered compatible for use while breastfeeding ([@bb0080], [@bb0405]) due to their large molecular size and the proteolytic environment in the neonatal gastrointestinal tract ([@bb0510]). Accordingly, clinical evidence is now available to support minimal to no transfer of CZP into breast milk ([@bb0125]). A recent study investigating the detection of biologics in breast milk from women treated for inflammatory bowel diseases (PIANO registry) also concluded that concentrations were low (maximum: 0.29-1.57 μg/mL) or not detectable (n = 43 of 72 women) in breast milk, with CZP demonstrating the lowest peak (infliximab \[n = 29\], adalimumab \[n = 21\], CZP \[n = 13\], ustekinumab \[n = 6\], natalizumab \[n = 2\], and golimumab \[n = 1\]; [@bb0330]). Nevertheless, a large proportion of dermatologists felt that breastfeeding women should either not be on anti-TNF therapy (EU5: 58%; U.S.: 43%) or indicated uncertainty (EU5: 31%; U.S.: 28%), highlighting the need for education in this area ([@bb0415]).

Conclusions {#s0075}
===========

PSO can profoundly affect people's quality of life and mental health; with the burden for women being particularly high. Compared with men, women experience lower levels of happiness and greater levels of stress, loneliness, stigmatization, and sexual impairment. The onset of PSO also often coincides with peak reproductive years for women, posing specific challenges for their treatment. Half of all pregnancies are unplanned; thus, it is critically important that, unless on adequate contraception, all women of childbearing age have a treatment plan that is compatible with pregnancy, irrespective of family planning intentions.

There is also a need for better information of HCPs with respect to therapeutic options for women of reproductive age, particularly in light of the increasing safety data available for biologic therapies, and for the establishment of formal treatment guidelines. Timely initiation of discussions by treating HCPs, and ongoing dialogue, with women of childbearing age with regard to compatible treatment options are required to optimize the care and outcomes for this patient population.

This article is accompanied by a Patient Page, a short summary to guide patients who may wish to access credible information with regard to PSO disease burden among women and their options with regard to their pregnancy journey.

Appendix A. Supplementary data {#s1005}
==============================

Supplementary figuresImage 1
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[^1]: ![](t2.gif)**Statistically significant**

[^2]: ![](t3.gif)**Not statistically significant**

[^3]: BMI, body mass index; LBW, low birth weight; LGA, large for gestational age; NR, not reported; PsA, psoriatic arthritis; PSO, psoriasis

[^4]: ^a^Previous abortion was adjusted for maternal age, gestational diabetes mellitus A2, and severe preeclampsia. Cesarean delivery was adjusted for previous cesarean delivery, malpresentation, hypertensive disorders, and labor dystocia.

[^5]: ^b^No adjusting for confounding factors was specified.

[^6]: ^c^Included 2553 pregnancies; outcomes were adjusted for maternal pre-pregnancy BMI, smoking, weekly alcohol consumption before pregnancy, and maternal age.

[^7]: ^d^Multivariate outcomes analysis was adjusted for ethnicity, marital status, education level, depression, hypertension, pregnancies per woman, age, BMI, hospital of delivery, diabetes, assisted reproductive technologies, substance abuse/cigarette smoking, medication use, anemia, and infection.

[^8]: ^e^Included 197 pregnancies; incidence rate ratios were adjusted for age.

[^9]: ^f^Outcomes analysis was adjusted for infant sex and parity, mother's age, education level, marital status, income, gestational hypertension, diabetes, anemia, and coronary heart disease, as well as the age and education level of the father.

[^10]: ^g^Multivariate analyses reported (Model 2) were adjusted for country, maternal age and parity, smoking status, BMI, depression, diabetes and hypertension; separate analyses were performed comparing women with severe and non-severe PSO with women without PSO.

[^11]: ^h^Moderate preterm birth only (32-36 weeks).

[^12]: This information is not intended to provide treatment recommendations. All disease management decisions must be based on discussion and agreement between the patient and treating physician.
